The public FDA record for Rapid-Medical, Ltd. centers on one premarket notification, K253146, for the Hyperdrive 35 Guidewire. The filing sits in product code DQX, described in the classification data as Wire, Guide, Catheter, under 21 CFR 870.1330, with a cardiovascular review panel and Class 2 designation. FDA recorded the submission as Traditional, reviewed by a third party, with a Summary rather than a full statement, and issued a Substantially Equivalent decision on September 18, 2026, after receiving it on September 25, 2025. The applicant address in the filing is Carmel Bldg., Pob 337, Yokneam, Israel, with Gutman Ina listed as contact; that is a filing address, not a confirmed corporate headquarters. [1][2][4]

The Hyperdrive 35 Guidewire filing

K253146 covers a device named Hyperdrive 35 Guidewire. FDA's record lists the applicant as Rapid-Medical, Ltd., the product code as DQX, the regulation as 21 CFR 870.1330, the device class as 2, and the advisory committee as Cardiovascular. The decision code is SESE, described as Substantially Equivalent, dated September 18, 2026. The clearance type is Traditional, the third-party review flag is Y, and the statement or summary field reads Summary. The combination product field is No, and no predetermined change control plan was authorized. [1][2][4]

An Innolitics device page for K253146 states the indications for use: the Hyperdrive 35 Guidewire is intended to direct a catheter to the desired anatomical location in the peripheral vasculature during diagnostic or interventional procedures. The same page identifies Radifocus Glidewire (K152740) as the legally marketed predicate device and Drivewire 24 Guidewire (K233791) as a reference device. Those relationships are reported by that publisher and are not restated in the FDA record cited here. [6]

Related Rapid-Medical records

A separate FDA premarket notification page, K233791, names Rapid-Medical, Ltd. as applicant for the Drivewire 24 Guidewire, classified under Guide, Wire, Catheter, Neurovasculature. That record appears in the numbered sources only as a partial page; its decision, dates and full classification details are not established here. Innolitics lists the same K233791 record as a reference device for K253146, which is consistent with the applicant name appearing on both filings. [8][6]

The DQX product-code listing published by Hardian Health shows the Hyperdrive 35 Guidewire, Rapid-Medical, Ltd., K253146, with a decision date of 2026-09-18, alongside other applicants' guidewire clearances in the same code. That listing is a third-party index of FDA authorizations, not a Rapid-Medical portfolio statement. [7]

What the collection shows

As of November 20, 2026, the linked collection contains one 510(k) record, K253146, and one decision, SESE. The record sample is the same single entry, so the sample decision count of one SESE matches the full collection count of one SESE. These figures describe the linked filings at that date and are not a measure of total company sales, total portfolio, commercial availability or safety performance. [1]

No recall records appear in the linked collection. That absence reflects the linked records only and does not establish a recall history either way. [1]

Identity and attribution

Rapid-Medical, Ltd. is identified in these records as the FDA legal applicant. The sources do not establish a parent company, brand owner, website, manufacturing site or corporate headquarters, and the Yokneam address on the filing should be read as applicant contact information. Device descriptions, predicate and reference device relationships, and indications for use are attributed to the publishers that reported them, including FDA records and the Innolitics device page. [1][4][6]